Compare GRBK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRBK | ARQT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | GRBK | ARQT |
|---|---|---|
| Price | $73.97 | $26.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $71.00 | $24.83 |
| AVG Volume (30 Days) | 225.1K | ★ 1.6M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.63 | N/A |
| Revenue | ★ $2,113,173,000.00 | $317,929,000.00 |
| Revenue This Year | N/A | $85.83 |
| Revenue Next Year | $3.35 | $30.72 |
| P/E Ratio | $9.57 | ★ N/A |
| Revenue Growth | 6.62 | ★ 129.21 |
| 52 Week Low | $50.57 | $11.13 |
| 52 Week High | $77.93 | $31.77 |
| Indicator | GRBK | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 64.01 | 43.38 |
| Support Level | $69.31 | $25.12 |
| Resistance Level | $75.00 | $26.93 |
| Average True Range (ATR) | 2.42 | 1.44 |
| MACD | 0.56 | -0.28 |
| Stochastic Oscillator | 84.69 | 27.53 |
Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.